Pembrolizumab and Paclitaxel in Patients with HR+/HER2− Breast Cancer with HER2-Enriched or Basal-like Subtypes
2026 · Clinical Cancer Research · 0 citations
https://doi.org/10.1158/1078-0432.ccr-25-2570
F
Fara Brasó-Maristany
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
0
Papers
0
Citations
Fara Brasó-Maristany is an academic researcher.
Papers by this author
worksChat about Author
Papers
Chat
Click to start Chat